Physician profile
Jacqueline Anders
NPI 1881075877
$3,296.18
in general payments reported to CMS, 2019-2025
23 companies · $806 in 2025
The $806 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $780 · 2022: $564 · 2023: $607 · 2024: $539 · 2025: $806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,951.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $756.68 | 2021-2025 | |
| Glaxosmithkline, LLC. | $570.35 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $419.45 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Axsome Therapeutics, INC. | $369.30 | 2024-2025 | Auvelity |
| Novo Nordisk INC | $264.02 | 2021-2025 | Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $196.92 | 2025 | Rexulti |
| Amgen INC. | $116.03 | 2021-2022 | |
| Organon LLC | $80.55 | 2025 | Jada System |
| Gilead Sciences, INC. | $65.16 | 2021 | |
| Abbott Laboratories | $59.66 | 2021-2023 | Freestyle Libre 2 |
| Xeris Pharmaceuticals, INC. | $52.95 | 2025 | Keveyis |
| Astrazeneca Pharmaceuticals Lp | $51.32 | 2021-2022 | |
| Astellas Pharma US INC | $40.72 | 2021-2023 | Myrbetriq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.25 | 2025 | Caplyta |
| Exact Sciences Corporation | $35.47 | 2023-2024 | Cologuard Collection Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $35.04 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.05 | 2021-2025 | Jardiance |
| Vanda Pharmaceuticals INC. | $27.20 | 2025 | Fanapt |
| Biohaven Pharmaceuticals, INC. | $22.45 | 2021 | |
| Dexcom, INC. | $17.67 | 2024 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $17.11 | 2023 | Seglentis |
| Merck Sharp & Dohme LLC | $16.80 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.03 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Anders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.